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Abstract: Rift Valley fever virus (RVFV) is a human and livestock pathogen endemic to 
sub-Saharan Africa.  We have developed a T7-dependent system for the efficient 
production of RVFV-like particles (RVF-VLPs) based on the virulent ZH-501 strain of 
RVFV. The RVF-VLPs are capable of performing a single round of infection, allowing for 
the study of viral replication, assembly, and infectivity. We demonstrate that these RVF-
VLPs are antigenically indistinguishable from authentic RVFV and respond similarly to a 
wide array of known and previously unknown chemical inhibitors. This system should be 
useful for screening for small molecule inhibitors of RVFV replication. 
Keywords: Rift Valley fever; virus-like particle; RNA virus; Bunyaviridae; Phlebovirus; 
minigenome; antivirals 
 
1. Introduction 
The Rift Valley fever virus (RVFV) is a vector and aerosol-borne virus endemic to sub-Saharan 
Africa. RVFV can cause disease in humans and in common livestock species, such as sheep and cattle. 
Pregnant animals exhibit a high incidence of abortion and young animals frequently succumb to 
infection [1]. People typically develop a flu-like illness, however, more severe manifestations, such as 
hemorrhagic fever or encephalitis, occur in a small percentage of cases. The hemorrhagic and 
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encephalitic forms of disease exhibit high case-fatality rates [2–4]. Competent vectors of RVFV are 
found worldwide [5–12], and release of the virus into a new region would be damaging for both the 
economy and public health. In 2000, the first documented outbreak of the virus outside of the African 
continent occurred on the Arabian Peninsula, and the virus was determined to be of East African 
origin [13–14]. The presence of the virus outside of Africa demonstrates the ability of the virus to 
spread to previously unaffected regions of the world, and geographic isolation appears to be mainly 
responsible for the containment of the virus to African regions. No licensed vaccines or therapeutic 
treatments are available; our RVF-VLP system will aid in the screening of small molecule inhibitors 
for the development of novel therapeutics. 
RVFV is an enveloped virus belonging to the Phlebovirusgenus of theBunyaviridaefamily. RVFV 
contains a negative-sense RNA genome that is divided into three segments, termed the small (S), 
medium (M), and large (L) segments. The S segment encodes the nucleocapsid protein (N), which 
encapsidates the viral RNA genome, and a nonstructural protein, NSs, which is involved in inhibition 
of the host innate-immune response [1]. The M segment encodes the envelope glycoproteins, Gn and 
Gc, and nonstructural proteins, termed NSm, while the L segment encodes an RNA-dependent RNA 
polymerase (RdRp). The nonstructural proteins, NSs and NSm are not required for viral replication in 
cell culture [15–18]. Transcription and replication of the viral genome is initiated through the 
recognition of promoter sequences in the 5’ and 3’ terminal untranslated regions (UTRs) of each 
genomic segment [19,20].  These processes occur in the cytoplasm and require both RdRp and N 
[1,21]. The RdRp and N are translated in the cytoplasm, while the envelope glycoproteins enter the 
secretory system. Gn and Gc form a complex and localize in steady-state to the Golgi apparatus due to 
a signal found on Gn [22–24]. The assembled virus buds into the lumen of the Golgi apparatus, and 
virions are released from the cell when elements of the Golgi fuse with the plasma membrane.  
We have developed a T7 RNA polymerase (T7 RNAP)-dependent system for the production of 
infectious RVFV-like particles (RVF-VLPs) that obviates the need for  high-level biosafety 
containment and allows for generation of viral particles that are antigenically indistinguishable from 
authentic RVFV. RVF-VLPs can deliver a minigenome to target cells and expression of RdRp and N 
in target cells is not necessary for generation of significant reporter activity. Minigenome activity is 
inhibited by the same chemical compounds that inhibit authentic RVFV replication. RVF-VLPs are 
efficiently produced in our system, which should allow for future studies aimed at examination of virus 
assembly and screening for small molecule inhibitors of viral entry and replication. 
2. Results 
2.1. System for Production of RVF-VLPs from ClonedcDNAs 
We utilized a set of plasmids similar to that described for rescue of the virulent ZH-501 strain of 
RVFV [16]  as the basis of our RVF-VLP system (Table 1).  In order to assess production of   
RVF-VLPs, a minigenome based on the S segment was generated such that the NSs open reading 
frame was replaced with a gene encoding a reporter molecule, such as GFP orrenillaluciferase (RLuc)  
(Figure 1a). Additionally, the vector backbone of all transcription plasmids was changed to one with 
transcriptional silencers flanking the cloning site (see Methods section). The new vector dramatically Viruses 2010, 2                         
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reduced the background expression of the reporter gene (data not shown). An additional transcription 
plasmid was constructed that lacked 237 nucleotides of the N gene (Figure 1a). Immunofluorescence 
microscopy (Figure 1b) and immuno-blot (data not shown) using a polyclonal antibody recognizing 
full-length N, failed to detect N expression. These S segment-based plasmids will henceforth be 
referred to as minigenome plasmids.  
A schematic detailing our method for RVF-VLP production and analysis is shown in Figure 1c. The 
minigenome along with expression plasmids for N, RdRp, and Gn/Gc are transfected into BSR-T7/5 
cells (Figure 1c). The BSR-T7/5 cells constitutively express T7 RNAP, which drives production of the 
primary minigenome transcript. Expression of the reporter from the minigenome in transfected cells 
requires co-expression of RdRp and N.  Co-expression of Gn/Gc results in the production of   
RVF-VLPs containing the minigenome (Figure 1c). The RVF-VLPs are released from the cells into the 
media, and are then used  to infect target cells (Figure  1c).  Replication of the minigenome and 
expression of RLuc or GFP in RVF-VLP-infected target cells relies on packaging of the 
encapsidatedminigenome and RdRp. The RVF-VLPs do not contain the L or M genomic segments. 
Additionally, the S segment-based minigenome lacks the NSs gene and, in some experiments,   
the N gene. Therefore, RdRp, Gn/Gc, and in some cases, N, cannot be synthesized in infected target 
cells and thus further production of RVF-VLPs is prevented. 
Table 1. Plasmids used in this study. 
Plasmid name  Description  Ref 
pTrRVFV-S∆NSs::GFP  S segment-based minigenomeplasmid. The 
NSs gene has been replaced with GFP. 
Primary transcription is mediated by T7 
RNAP.  Vector backbone derived from 
pSP64 (Promega). 
 [16] 
pRdRp  RdRp ORF cloned into pVAX1 
(Invitrogen). Contains T7 RNAP and CMV 
promoters. 
This study 
pRdRp-Amp (pSRG309)  RdRp ORF cloned into pIRES (Clontech). 
Contains T7 RNAP and CMV promoters. 
This study 
pN  N ORF cloned into pVAX1 (Invitrogen). 
Contains T7 RNAP and CMV promoters. 
This study 
pSTrRVFV-S∆NSs::hRLuc 
 
S segment-based minigenomeplasmid. The 
NSs gene has been replaced with hRLuc. 
Primary transcription is mediated by T7 
RNAP. Vector backbone is pSMART HC 
Kan (Lucigen). 
This study 
pSTrRVFV-
S∆N∆NSs::hRLuc 
Derived from pSTrRVFV-S∆NSs::hRLuc, 
the SmaI fragment within the N gene has 
been removed. 
This study 
pGn/Gc  Gn/Gcpolyprotein ORF cloned into 
pcDNA1.1 
 [22] 
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Figure 1. (a)  Schematic of RVFV S segment-based minigenome and procedure for 
generation and analysis of RVF-VLPs. The minigenome plasmids are derived from the  
S-segment. The minigenome is flanked by a T7 promoter (T7P) and hepatitis delta 
ribozyme (δRz) and T7 terminator (T7T). T7 RNA polymerase (RNAP)  initiates 
transcription at the final G residue in the promoter and terminates at the T7T  site. 
Following transcription, the δRz excises itself to generate an authentic viral 3’ terminus. 
The 5’ and 3’ UTRs are indicated by hashed marks and the intergenic region is indicated in 
black.  (b)  Internal deletion in N ORF prevents expression from ∆N minigenome.  
BSR-T7/5 cells were either transfected with empty vector (EV) or transfected with 
minigenome or ∆N minigenome. Cells were fixed 24 h post-transfection and incubated 
with rabbit anti-N polyclonal antibody, followed by Alexa Fluor 488 mouse anti-rabbit 
secondary antibody. Slides were mounted in Prolong antifade with Dapi. (c) Schematic of 
RVF-VLP production.  Minigenome along with expression plasmids for N, RdRp, and 
Gn/Gc are transfected into BSR-T7/5 cells.  The expression constructs have the open 
reading frames downstream of T7 (T7P) and CMV promoters (CMVP) and are followed by 
polyadenylation signals (pA), generating high-level constitutive expression of the genes. 
Theminigenome is first transcribed by T7 RNAP followed by replication and transcription 
of the RNA by the RdRp and N. Transcription of the reporter gene on the minigenome 
results in production of the reporter molecule (RLuc or GFP). Expression of Gn and Gc 
results in packaging of the minigenome into RVF-VLPs that can be harvested and used to 
infect target cells. In target cells the minigenome is transcribed by the packaged RdRp, 
resulting in expression of the reporter molecule. 
(a)     
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Figure 1. Cont. 
(c)    
 
2.2. Production of Infectious RVF-VLPs. 
We investigated the ability of the recombinant structural proteins, N, RdRp and Gn/Gc, to replicate 
and transcribe the minigenome in transfected BSR-T7/5 cells. Replication of the minigenome requires 
expression of N and RdRp, but not Gn/Gc[21]. Cells transfected with minigenome and pN, but not 
pRdRp and pGn/Gc were unable to transcribe the minigenome reporter (Table 2, EV/EV), and the 
RLuc activity in these samples was considered background. The addition of pRdRp resulted in RLuc 
activity at levels greater than 1,500-fold background levels (Table 2, RdRp/EV). Though Gn/Gc is not 
required for replication of the minigenome, Gn/Gc expression further increased the production of 
RLuc in transfected cells to levels greater than 40,000-fold background (Table 2, RdRp/Gn/Gc). The 
increase in RLuc expression could be due to an effect of Gn/Gc on RdRp activity or due to   
RVF-VLP-infection of other cells in the monolayer.  
Table 2. Gn/Gc increases RLuc expression in transfected cells. 
Sample 
Average  
Log Raw Luciferase Units (RLU)  
EV/EV  3.76 
RdRp/EV  6.94 
RdRp/Gn/Gc  8.37 
 
RVF-VLPs released into the media from the cells transfected in Table 2 were used to infect various 
target cells, and RLuc expression in the RVF-VLP-infected target cells was measured. Cells receiving 
media from cells transfected with minigenome, pN, pRdRp (RdRp/EV) did not generate RLuc 
expression greater than background for any timepoint or cell type investigated. By contrast, target cells 
receiving media from cells transfected with minigenome, pN, pRdRp, and pGn/Gc (RdRp,Gn/Gc) 
produced RLuc activity substantially above background for all timepoints and cell types   
(Table 3).  Therefore, infectious RVF-VLP production is dependent on expression of Gn/Gc.   
The production of RVF-VLPs peaked at 48 h post-transfection, however considerable amounts of 
RVF-VLPs were released at 72 h post-transfection (Table 3). 
RLuc activity in RVF-VLP-infected target cells did not require expression in trans of the T7 RNAP 
or RdRp and N. RVF-VLP-infection of Vero E6 cells, which do not express the T7 RNAP or any viral 
proteins, produced RLuc levels that were over 200-fold background (Table 3). However, the addition 
of support plasmids did increase RLuc activity in BSR-T7/5 and Vero E6 cells. For instance, at the  Viruses 2010, 2                         
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48 h timepoint, expression of RdRp and N in BSR-T7/5 cells increased RLuc activity greater than  
15-fold and expression of RdRp in Vero E6 cells increased RLuc activity 1.8-fold (Table 3). 
Table 3. RdRp expression in trans enhances RLuc expression in target cells. 
2.3. RVF-VLPs are Efficiently Produced 
Using the green fluorescent protein (GFP) version of the minigenome, we investigated whether the 
increase in RLuc activity in transfected cells due to expression of Gn/Gc (Table 2) was caused by 
RVF-VLP infection of cells in the transfected cell monolayer. BSR-T7/5 cells transfected with the 
GFP minigenome, pN, and either empty vector (EV/EV), pRdRp and empty vector (RdRp/EV), or 
pRdRp and pGn/Gc(RdRp/Gn/Gc), were visualized by fluorescence microscopy (Figure  2a).  
As expected, no GFP signal was detected in cells that lacked RdRp and Gn/Gc (Figure 2a, EV/EV). 
However, in cells that expressed RdRp (RdRp/EV), or RdRp and Gn/Gc (RdRp/Gn/Gc) GFP 
expression was evident (Figure 2a). Although the signal intensity increased over time in cells that 
lacked Gn/Gc, the percentage of cells expressing GFP did not increase (Figure 2a). With addition of 
the glycoproteins (RdRp/Gn/Gc), the intensity of GFP fluorescence as well as the percentage of cells 
expressing GFP increased over time (Figure  2a).  Therefore, it appears that the increase in RLuc 
activity observed in the experiment shown in Table 2 is mainly due to spread of RVF-VLPs in the 
transfected cell monolayer 
The media harvested from the transfected cells (Figure 2a) at 24, 48, or 72 h post-transfection was 
placed onto target cells and GFP expression was visualized by fluorescent microscopy (Figure 2b).  
The passage from cells lacking Gn/Gc did not produce any GFP, while passage from cells expressing 
Gn/Gc did exhibit GFP expression in target cells. The number of cells expressing GFP and the 
intensity of GFP expression was greatest for cells infected with RVF-VLPs (RdRp/Gn/Gc) harvested 
48 h post-transfection. However, RVF-VLP production appeared to exhibit high yields at 72 h   
post-transfection, mimicking the RLuc results shown in Table 3. The majority of the cells in the 
monolayer appeared to express GFP after RVF-VLP (RdRp/Gn/Gc) infection, demonstrating that 
RVF-VLPs were efficiently produced. 
VLP 
Harvest  
(hpt) 
Sample 
BSR-T7/5 
(Log RLU/mL) 
BSR-T7/5  
RdRp/N-expressing 
(Log RLU/mL) 
Vero 
(Log RLU/mL)  
Vero 
RdRp-expressing 
(Log RLU/mL) 
24 
EV/EV  3.21  3.71  3.22  3.24 
RdRp/EV  3.25  3.55  3.22  3.23 
RdRp/Gn/Gc  5.38  6.36  4.50  4.93 
48 
RdRp/EV  3.80  4.42  3.69  3.70 
RdRp/Gn/Gc  7.08  8.31  6.15  6.41 
72 
RdRp/EV  3.28  4.01  3.23  3.26 
RdRp/Gn/Gc  6.04  7.54  5.10  5.37 Viruses 2010, 2                         
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Figure 2. (a) Cells were transfected with the GFP minigenome, pN and either empty vector 
(EV/EV), pRdRp and empty vector (RdRp/EV), or pRdRp and pGn/Gc (RdRp/Gn/Gc) and 
analyzed at the indicated times for expression of GFP. (b) Media from cell monolayers 
shown in (a) was harvested at the indicated times and used to infect BSR-T7/5 cells that 
expressed RdRp and N. 
(a) 
b. 
 
2.4. RVF-VLPs are Antigenically Indistinguishable from Authentic RVFV 
BSR-T7/5 cells were transfected with minigenome, pN, pRdRp, and pGn/Gc. The media containing 
RVF-VLPs was harvested and clarified, then, incubated with antibodies recognizing RVFV or not 
incubated with antibody (Mock). The media was then transferred to BSR-T7/5 target cells and RLuc 
activity was measured at 24 h post-infection. The level of RLuc activity in cells infected by RVF-VLPs 
receiving the Mock treatment represents 100% infectivity (Figure 3). Incubation of the RVF-VLPs 
with neutralizing polyclonal antibodies to RVFV nearly completely neutralized the RVF-VLPs, and 
resulted in minigenome activity levels that were only 1% of the Mock treatment (Figure 3). Incubation 
with neutralizing monoclonal antibodies recognizing the envelope glycoproteins [25], which are 
exposed on the surface of the RVF-VLPs, neutralized the RVF-VLPs dramatically, allowing only 6% 
activity (Figure 3). By contrast, monoclonal antibodies recognizing N, which is not exposed on the Viruses 2010, 2                         
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surface of the RVF-VLPs, did not significantly reduce infectivity of the RVF-VLPs (Figure  3).  
These antibodies were evaluated on the same strain of RVFV (ZH-501) that was used to generate our 
VLP system  (data not shown), and the same trends were observed.  Our results suggest that the   
RVF-VLPs are antigenically similar to virulent RVFV. 
Figure 3. RVF-VLPs are neutralized by the same antibodies that neutralize RVFV. RVF-
VLPs that were generated and subjected to a 30 min incubation at room temperature with 
no antibody, monoclonal anti-N, neutralizing anti-Gn and anti-Gcmonoclonals or a 
polyclonal anti-RVFV antibody prior to application on target cells.  The antibody 
concentration effective for neutralization was determined on authentic RVFV. The target 
cells were harvested at 24 h post-infection and the RLuc activity levels were measured. 
RLuc values (RLU) are expressed relative to the no antibody control. Shown is the data for 
a representative experiment performed in triplicate with standard deviation bars. 
 
2.5. RVF-VLPs are Efficiently Harvested by High-Speed Centrifugation 
We devised a method for harvesting the RVF-VLPs in order to assay cellular release of particles 
and to determine the protein content of RVF-VLPs.  BSR-T7/5 cells were transfected with 
minigenome, pN, pRdRp, and either pGn/Gc or empty vector. At 48 h post-transfection, the media 
from transfected cells was harvested, clarified, and RVF-VLPs were pelleted by ultracentrifugation. 
The concentrated RVF-VLPs in the pellet were either resuspended in the supernatant (Figure 4; Pellet 
+ Supernatant) or the supernatant was decanted (Figure 4; Supernatant) and the pellet was resuspended 
in equivalent amount of fresh media (Figure 4; Pellet). These samples were used to infect BSR-T7/5 
cells that expressed RdRp and N. At 24 h post-infection, the cells were harvested and RLuc activity 
was measured. RLuc activity in BSR-T7/5 cells that were infected with the passage containing both the 
supernatant and pellet fractions represents 100% infectivity. Nearly 80% of the infectivity was present 
in the pellet, while only 3% of the infectivity was in the supernatant. Presumably, the decrease in RLuc 
activity between the “Pellet and Supernatant” and “Pellet” samples is due to RVF-VLP loss when the 
media was decanted. Viruses 2010, 2                         
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Figure 4. RVF-VLPs can be harvested using high-speed centrifugation. Clarified media 
from transfected cells was subjected to high-speed centrifugation as described in the 
materials and methods. The “Supernatant”,“Pellet” or “Pellet + Supernatant” were used to 
infect target cells. RLuc activity was measured at 24 h post-infection and is expressed in 
relative RLuc units.  Shown is the data for a representative experiment performed in 
quadruplicate, the error bars reflect the standard deviation. 
 
2.6. RVF-VLPsBehave Similar to Authentic RVFV with Respect to Small Molecule Inhibitors 
We tested a panel of small molecule inhibitors for activity against RVF-VLPs and RVFV. Two of 
these compounds, ribavirin[26–29] and actinomycin D[30], had previously been tested for activity 
against RVFV and thus serve as positive controls. Ribavirin is a broad spectrum antiviral that  is 
believed to inhibit viral replication either by directly acting on the RdRp or indirectly through 
inhibition a cellular enzyme necessary for biosynthesis of guanine nucleotides [31]. Actinomycin D 
was investigated due to its ability to inhibit cellular DNA-dependent RNA polymerases but not viral 
RNA-dependent RNA polymerases [32]. Guanidine and mycophenolic acid were tested because they 
have been shown to have activity against other RNA viruses. Guanidine is active against the RdRp of 
poliovirus and many other positive-sense RNA viruses [33] and has been also been shown to inhibit 
the RdRp of a dsRNA virus [34].  Mycophenolic acid acts on the same cellular enzyme as 
ribavirin [31,35]. And finally, monensin and ammonium chloride block the acidification of endocytic 
organelles [36]. The acidic organelles are required for membrane fusion for many viruses that enter 
host cells through receptor-mediated endocytosis.  
The inhibitors were added to the cultures at the time of infection with either RVF-VLPs or RVFV. 
Infected cells were harvested at 22 h post-infection and minigenome activity or expression of N was 
assayed, respectively. As expected, ribavirin was found to be a potent inhibitor of RVF-VLPs  
(Table 4) and RVFV (Figure 5). Mycophenolic acid was also a strong inhibitor (Table 4, Figure 5), 
suggesting that  inhibition of guanine nucleotide biosynthesis is sufficient for inhibition of viral 
replication. The endocytic inhibitors, ammonium chloride and monensin, inhibited both RVF-VLPs 
(Table 4) and RVFV (Figure  5), suggesting that the virus enters cells through receptor-mediated Viruses 2010, 2                         
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endocytosis.  Guanidine did not strongly inhibit either RVF-VLPs (Table 4) or RVFV (Figure  5). 
Actinomycin D blocked activity of RVF-VLPs (Table 4) but did not inhibit RVFV  (Figure  5). 
Recently, Ikegami et al. discovered the combination of RVFV (MP12 strain) replication and host 
transcriptional repression, either by actinomycin D or RVFV NSs, was sufficient to induce the 
activation of protein kinase R (PKR) [37]. PKR inhibits translation of host and viral proteins, but can 
be targeted for degradation by RVFV NSs [30,37].  The RVF-VLPs do not express NSs, so the 
induction of PKR by actinomycin D cannot be down-regulated. 
3. Discussion 
In this paper we report on the development of a T7-dependent system for production of RVF-VLPs 
and its application to high-throughput screening for antivirals against RVFV. We are able to generate 
RVF-VLPs through the expression of a minigenome and four viral structural proteins;Gn, Gc, N and 
RdRp. Although these particles lack the full complement of genomic segments, they behave in a 
similar fashion to authentic RVFV in the four respects tested in this study. (1) RVF-VLPs are able to 
package a minigenome based on the S segment and deliver it to naive target cells. (2) RVF-VLPs are 
secreted from the cell and can be concentrated from the media by centrifugation. (3) RVF-VLPs are 
inhibited from infection of a naive monolayer by antibody neutralization using the same set of 
antibodies that neutralize RVFV. (4) Chemical inhibitors of RVFV replication also inhibit RVF-VLPs 
indicating that the minigenome activity is an appropriate surrogate for viral replication.  
Plasmid-based genetic and RVF-VLP systems are powerful tools for studying the replicative cycle 
of viruses. We have modified the design of the T7 RNAP-driven plasmid-based rescue system for the 
virulent ZH-501 RVFV strain [16] in order to produce RVF-VLPs capable of performing only a single 
round of infection.  In our design, expression plasmids encoding the open-reading frames of the 
structural proteins were expressed along with a minigenome. The expression plasmids do not contain 
the 5’ and 3’ UTRs that have been demonstrated to be required for packaging of the genome [19,20]. 
Thus, the RNAs produced from these plasmids cannot be packaged and these RVF-VLPs are capable 
of only a single round of replication. Using our system, we efficiently generated infectious RVF-VLPs. 
Detection of minigenome activity in target cells was robust, and did not require expression of any 
RVFV proteins or T7 RNAP. Therefore, RVF-VLPs can be used to deliver minigenome to cells that 
are not efficientlytransfected, such as mosquito cells. Minigenome activity in RVF-VLP-infected target 
cells was reduced to near background levels by ribavirin, mycophenolic acid, ammonium chloride and 
monesin, all of which were also shown to be active against RVFV. Mycophenolic acid, ammonium 
chloride and monensin had not been tested previously for activity against RVFV. The results obtained 
with ammonium chloride and monensin, suggest that RVFV enters cells through receptor-mediated 
endocytosis. Our results are the first to examine endocytic entry by RVFV in the context of authentic 
RVFV infection. However, previous studies exploring the ability of the RVF envelope glycoproteins to 
form syncitia using either baculovirus or alphavirus-driven expression systems have previously found 
syncitia formation to be pH dependent [38,39]. Interestingly, we saw a differential effect with 
actinomycin D, in that this compound inhibits RVF-VLPs but not RVFV. Recently it has been shown 
that NSs from either MP12 (vaccine) or ZH-548 (virulent) strains is capable of degrading PKR [30,37]. 
Thus, it is likely that the differential effect we see with actinomycin D is because RVF-VLPs do not Viruses 2010, 2                         
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express NSs. However we cannot rule out the possibility that the differential effect of actinomycin D is 
the result of an inherent difference between how infected cells respond to RVFV versus RVF-VLPs. 
 Figure 5: Effect of small molecule inhibitors on RVFV replication. Inhibitors were added 
at the indicated concentrations at the time of infection with the ZH548-MP12 vaccine 
strain of RVFV at an MOI of 1. At 22 h post-infection, cells were fixed and stained with 
rabbit anti-N followed by anti-rabbit Alexa 488. The nuclei were visualized with Dapi. 
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Table 4. Effect of chemical inhibitors on RVF-VLP delivered minigenome activity. 
Inhibitor  Concentration  % Activity 
 Mock (water)  -  100 
Ammonium chloride  5 mM  9.7 
  10 mM  1.3 
  20 mM  0.5 
Guanidine  25 µg/mL  45.8 
  50 µg/mL  19.2 
  100 µg/mL  22.4 
Ribavirin  25 µg/mL  12.8 
  50 µg/mL  6.2 
  100 µg/mL  4.3 
Mock (ethanol)  -  100 
Actinomycin D  0.5 µg/mL  13.2 
  1.0 µg/mL  6.4 
  2.0 µg/mL  5.2 
Monensin  0.1 µM  58.2 
  1.0 µM  2.1 
  10.0 µM  0.2 
Mycophenolic acid  1.0 µM  48.6 
  10.0 µM  8.9 
  100.0 µM  5.8 
Taken together our results strongly suggest that RVF-VLPs may serve as effective screening tools 
for identification of antivirals with activity against RVFV.  The RVF-VLPs obviate the need for 
operating under select agent guidelines and BSL-3Ag conditions, which would be necessary if using 
virulent RVFV. Our replicon assay produced activity levels over 1,500-fold background, while our 
signal-to-noise values for the minigenome delivered by RVF-VLPs were found to be as high as 7,800. 
This value was obtained without any concentration of RVF-VLPs. Therefore, we have highly sensitive 
assays for both replication/transcription and RVF-VLP infectivity.  Additionally, the RVF-VLPs 
express RLuc, thus they provide for a method of determining inhibition in a format that can be scaled 
to high-throughput levels. Furthermore, while the vaccine strain of RVFV (MP12) is cytopathic and 
can be used for high-throughput screening under BSL2 conditions, RVF-VLPs have the advantage of 
allowing for screening forsmall molecules  that inhibit discreet viral processes  and the ability to 
identify molecules that increase replication. For instance, RVF-VLPs can be used to screen specifically 
for effects on replication or entry into cells, thus making it easier to identify the target of inhibitory or 
enhancing molecules identified in a screen. Additionally, our RVF-VLPs are based on a virulent strain 
of RVFV, thus eliminating the potential of attenuating mutations influencing the activity of 
compounds.  
We are using the RVF-VLPs system to study various steps in the RVFV replicative cycle, including 
entry, replication, assembly, and budding. The RVF-VLP system can be used to identify the viral 
proteins and genome elements necessary for the production of infectious RVF-VLPs, as well as 
elucidate the role of individual protein domains. Since expression of N or RdRp in target cells is not Viruses 2010, 2                         
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required for detection of RVF-VLP infection, we can analyze the effect of mutation on all of the 
structural proteins in order to identify protein-protein and protein-RNA interactions that are essential to 
virus assembly. Identification of critical protein domains will allow us to not only screen, but also 
design small molecule inhibitors targeting these important regions for the development of specific 
therapeutics. 
4. Experimental Section 
4.1. Plasmids 
The construction of pTrRVFV-S∆NSs::GFP, pSTrRVFV-∆NSmM, pN-Amp, and pGn/Gc have 
been described elsewhere[16,22].  pSTrRVFV-S∆NSs::hRLuc was derived from pTrRVFV-
S∆NSs::GFP in several steps. First, the GFP gene was released by digestion with EcoRV, followed by 
ligation with a humanized renillaluciferase gene (RLuc) that was flanked by EcoRV sites.  The 
resulting plasmid was then subcloned into pSMART HC Kan (Lucigen). pSTrRVFV-
S∆N∆NSs::hRLuc was derived from pSTrRVFV-S∆NSs::hRLuc by removing the 237 nucleotide 
SmaI fragment. pRdRp-Amp (pSRG309) is derived from the L segment plasmid, pTrRVFV-L [16]. In 
brief, the RdRp ORF was amplified from pTrRVFV-L with primers that containedSalI (5’) and NotI 
(3’) sites. The resulting PCR product was then cloned into the SalI/NotI site of pIRES (Clontech) and 
the IRES was subsequently removed by digest of the plasmid with XhoI and SalI. The expression 
plasmids pN and pRdRp were constructed by cloning the open reading frames for N and RdRpinto 
pVAX1 (Invitrogen) using HindIII/EcoRI and BamHI/NotI sites, respectively. 
4.2. Cells and Virus 
Vero E6 and BSR-T7/5 cells were generous gifts from Dr. C. Fulhorst (University of Texas Medical 
Branch, Galveston) and Dr. K. Conzelmann (Max-von Pettenkofer-Institut, Munchen, Germany), 
respectively. BSR-T7/5 cells were subsequently cloned by limiting dilution and the resulting clonal 
lines were tested using the RVFV minigenome that expresses RLuc. Lines that produced high levels of 
RLuc from the minigenome were expanded. The C3 clone of the BSR T7/5 line was used for all 
experiments. The BSR-T7/5 and Vero E6 cells were grown in Dulbecco’s Modified Eagle Medium 
(Invitrogen) supplemented with 10% FCS and sodium pyruvate. The T7 RNAP transgene in the BSR-
T7/5 cells was selected for using 1 mg/mLGeneticin (Invitrogen). The Vero E6 cells that stably 
express the RVFV RdRp (Vero E6-RdRp) were generated by transfection of Vero E6 cells with 
pSRG309 and pcDNA-Hygromycin (Invitrogen), then selection of hygromycin resistant cells with 
200µg/mL hygromycin (Invitrogen).  The ZH548-MP12 vaccine strain of RVFV used for all 
experiments involving infectious virus and was obtained from Dr. R. Tesh (World Reference Center of 
Emerging Viruses and Arboviruses). 
4.3. Antibodies 
Hybridomas that secrete neutralizing monoclonal antibodies that recognize Gn and Gc (R1-4B6-1-
2, R1-4D4-1-1 and R5-3G2-1A) and monoclonal antibodies recognizing N (R1-P6-F6-6-2-2, R1-P6-
F6-10-1-1, R1-P5-A6-12-2-2, RV-V-1B9-1-1, R3-1D8-1-2 and RV5-V6E4-1-1) were a generous gift Viruses 2010, 2                         
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of Dr. G. Ludwig (USAMRIID). Polyclonal antibodies that were generated against RVFV in mice 
were a generous gift of Dr. P. Rollin (CDC). Full-length N was expressed with an N-terminal histidine 
tag and purified under denaturing conditions on a Ni-NTA agarose column (Qiagen Inc.). The N 
antibody was generated in rabbits using purified protein as antigen (Harlan Laboratories).  The 
secondary antibody used in immunofluorescence experiments was Alexa Fluor 488 goat anti-rabbit 
(Molecular Probes). 
4.4. Virus-Like Particle Production 
BSR-T7/5 cells were plated at 1 x 10
5 cells/well in 12-well culture plates. After 24 h, cells were 
transfected using 2 µL/µgTransIT LT1 (Mirus Corporation) and plasmids in the ratio 0.25 µg 
minigenome: 0.50µg pN: 0.75 µg pRdRp: 0.50 µg pGn/Gc. Media on transfected cells was replaced 
every 24 h. Media containing RVF-VLPs was typically harvested at 48 or 72 h post-transfection, 
clarified by low speed centrifugation (300 rcf for 10 min at 4˚C) and then diluted prior to being used to 
infect target cells. For some experiments target cells were transfected with pRdRp and pN 24 h prior to 
infection. Target cells were harvested at 24 h post-infection, and were analyzed by either fluorescence 
microscopy or RLuc assay (Promega). For some experiments, RVF-VLPs were concentrated. In those 
cases, clarified media was centrifuged at 82,700 rcf for 4 h at 4 ˚C . The supernatant was removed and 
the pellet was resuspended in complete media. 
4.5. RVFV Inhibitor Screen 
Concentrated stocks of inhibitors were prepared either in water and filter sterilized (ribavirin, 
ammonium chloride, guanidine) or 100% ethanol (monensin, mycophenolic acid, actinomycin D). The 
inhibitors were obtained from Sigma-Aldrich (monensin, actinomycin D, guanidine), Calbiochem 
(mycophenolic acid), VWR (ammonium chloride) and RPI Corporation (ribavirin). RVF-VLPs and the 
ZH548-MP12 vaccine strain of RVFV (at an MOI of 1) were diluted 1:1 with 2X concentration of 
inhibitors in complete media. After 22 hours incubation, the inhibitors were removed and cells were 
analyzed for RLuc expression (RVF-VLPs) or immune fluorescence microscopy (RVFV-infected). 
4.6. Immunofluorescence Microscopy 
Cells were plated on glass coverslips and were fixed using freshly prepared 4% paraformaldehyde 
(Sigma-Aldrich) for 30 minutes. The paraformaldehyde was removed and cells were washed with PBS 
containing 1% BSA (PBS/BSA). The cells were permeabilized with PBS/BSA containing 0.1% Triton-
X100 (Shelton Scientific, Inc.) for 30 minutes, then washed with PBS/BSA before adding the primary 
antibody. The primary antibody in all experiments was rabbit anti-N. The cells were washed again, and 
the secondary antibody goat anti-rabbit A488 (Molecular Probes) was added and incubated in the dark 
for 1 h.  Finally, the cells were washed thoroughly and mounted onto glass slides using Prolong 
Antifade Gold with Dapi (Molecular Probes). The fluorescence was visualized using an Olympus BX-
51 microscope in the University of Michigan Microscopy and Image Analysis Laboratory. 
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5. Conclusions 
Our T7 RNAP-dependent VLP system efficiently generates RVF-VLPs, which are antigenically 
indistinguishable from authentic virus and behave similarly to chemical inhibitors. The sensitivity and 
design of the RVF-VLP system should allow for analysis of small molecule inhibitors of RVFV 
replication and entry in high-throughput format. 
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